BSE Live
Oct 31, 16:01Prev. Close
5301.75
Open Price
5293.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 31, 15:59Prev. Close
5318.00
Open Price
5322.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5209.00 (5)
| Profit & Loss account of Pfizer (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 2,281.00 | 2,192.69 | 2,422.32 | 2,610.55 | 2,238.43 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 2,281.00 | 2,192.69 | 2,422.32 | 2,610.55 | 2,238.43 | |
| Total Operating Revenues | 2,281.35 | 2,193.17 | 2,424.76 | 2,610.99 | 2,238.55 | |
| Other Income | 172.25 | 180.51 | 101.05 | 62.65 | 81.12 | |
| Total Revenue | 2,453.60 | 2,373.68 | 2,525.81 | 2,673.64 | 2,319.67 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 272.34 | 335.80 | 345.27 | 354.29 | 334.74 | |
| Purchase Of Stock-In Trade | 512.75 | 468.59 | 471.92 | 666.64 | 448.65 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 25.36 | -11.82 | 56.48 | -72.90 | 14.35 | |
| Employee Benefit Expenses | 371.33 | 347.80 | 331.68 | 403.67 | 361.06 | |
| Finance Costs | 8.41 | 15.41 | 13.39 | 10.49 | 15.11 | |
| Depreciation And Amortisation Expenses | 60.79 | 62.28 | 105.51 | 115.00 | 109.41 | |
| Other Expenses | 359.34 | 417.50 | 410.55 | 423.56 | 367.63 | |
| Total Expenses | 1,610.32 | 1,635.56 | 1,734.80 | 1,900.75 | 1,650.95 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 843.28 | 738.12 | 791.01 | 772.89 | 668.72 | |
| Exceptional Items | 172.81 | 7.95 | 33.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 1,016.09 | 746.07 | 824.01 | 772.89 | 668.72 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 264.10 | 158.92 | 251.82 | 218.33 | 183.63 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -15.61 | 36.11 | -51.91 | -35.93 | -12.52 | |
| Tax For Earlier Years | 0.00 | -0.29 | 0.17 | -22.07 | 0.00 | |
| Total Tax Expenses | 248.49 | 194.74 | 200.08 | 160.33 | 171.11 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 767.60 | 551.33 | 623.93 | 612.56 | 497.61 | |
| Profit/Loss From Continuing Operations | 767.60 | 551.33 | 623.93 | 612.56 | 497.61 | |
| Profit/Loss For The Period | 767.60 | 551.33 | 623.93 | 612.56 | 497.61 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 136.46 | 120.51 | 128.50 | 133.89 | 108.77 | |
| Diluted EPS (Rs.) | 167.79 | 120.51 | 136.38 | 133.89 | 108.77 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 160.13 | 182.99 | 297.35 | 160.12 | 1,509.66 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 1,650.00 | 350.00 | 700.00 | 350.00 | 350.00 | 
03.10.2025
Why Pfizer struck a drug-pricing deal with the Trump administration
01.10.2025
Trump unveils 'TrumpRx' website for cheaper drugs, Pfizer promises up to 50% discounts | Explained
22.09.2025
14.08.2025
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
30.07.2024
Pfizer Standalone June 2024 Net Sales at Rs 562.86 crore, up 5.93% Y-o-Y
20.05.2024
Pfizer Standalone March 2024 Net Sales at Rs 546.63 crore, down 4.54% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011